Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Targeting metabolic dependencies in pediatric cancer.

Issaq SH, Heske CM.

Curr Opin Pediatr. 2020 Feb;32(1):26-34. doi: 10.1097/MOP.0000000000000853.

PMID:
31789976
2.

Targeting Glycolysis through Inhibition of Lactate Dehydrogenase Impairs Tumor Growth in Preclinical Models of Ewing Sarcoma.

Yeung C, Gibson AE, Issaq SH, Oshima N, Baumgart JT, Edessa LD, Rai G, Urban DJ, Johnson MS, Benavides GA, Squadrito GL, Yohe ME, Lei H, Eldridge S, Hamre J 3rd, Dowdy T, Ruiz-Rodado V, Lita A, Mendoza A, Shern JF, Larion M, Helman LJ, Stott GM, Krishna MC, Hall MD, Darley-Usmar V, Neckers LM, Heske CM.

Cancer Res. 2019 Oct 1;79(19):5060-5073. doi: 10.1158/0008-5472.CAN-19-0217. Epub 2019 Aug 20.

PMID:
31431459
3.

Glutamine synthetase is necessary for sarcoma adaptation to glutamine deprivation and tumor growth.

Issaq SH, Mendoza A, Fox SD, Helman LJ.

Oncogenesis. 2019 Feb 26;8(3):20. doi: 10.1038/s41389-019-0129-z.

4.

Bioenergetic properties of human sarcoma cells help define sensitivity to metabolic inhibitors.

Issaq SH, Teicher BA, Monks A.

Cell Cycle. 2014;13(7):1152-61. doi: 10.4161/cc.28010. Epub 2014 Feb 10.

5.

Sec5 and Exo84 foster oncogenic ras-mediated tumorigenesis.

Issaq SH, Lim KH, Counter CM.

Mol Cancer Res. 2010 Feb;8(2):223-31. doi: 10.1158/1541-7786.MCR-09-0189. Epub 2010 Feb 9.

Supplemental Content

Loading ...
Support Center